Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Carbidopa/levodopa/folic acid compound medicine composition and use thereof

A technology of levodopa and a composition is applied in the field of pharmacy to achieve the effects of reducing stroke, increasing curative effect, preventing and stroke

Inactive Publication Date: 2013-06-05
SUZHOU FAMO BIOLOGICAL TECH
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Entocapone is 100-200 mg each time, and the frequency of taking the compound levodopa is the same as that of the compound levodopa. Levodopa taken together, single use is invalid

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carbidopa/levodopa/folic acid compound medicine composition and use thereof
  • Carbidopa/levodopa/folic acid compound medicine composition and use thereof
  • Carbidopa/levodopa/folic acid compound medicine composition and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1. Preparation of tablet

[0035] prescription:

[0036]

[0037] Preparation Process:

[0038] (1) Take the carbidopa, levodopa and folic acid of the prescribed amount and pass through a 100 mesh sieve and mix them uniformly by the method of equal increments for subsequent use;

[0039] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0040] (3) Mix the starch, microcrystalline cellulose, and CMS.Na according to the prescription amount, and then mix them evenly with the mixed raw material drug in equal increments;

[0041] (4) Add an appropriate amount of binder to prepare soft materials, granulate with a 24-mesh sieve, granulate with a 20-mesh sieve, and dry at 40-75°C.

[0042] (5) Add an appropriate amount of magnesium stearate to the dry granules and mix evenly. After the content is determined, compress into tablets and pack.

[0043] 3 times a day, 1 tablet each time.

Embodiment 2

[0044] Embodiment 2. The preparation of capsule

[0045] prescription:

[0046]

[0047] Preparation Process:

[0048] According to the prescription ratio, take lactose, microcrystalline cellulose, starch, and sodium starch glycolate and dry them at about 100°C for about 2 hours to pass through a 100-mesh sieve; after passing the raw material through a 100-mesh sieve, mix with the above-mentioned excipients in equal amounts Evenly, capsule filling.

[0049] 3 times a day, 1 capsule each time.

Embodiment 3

[0050] Example 3. Preparation of Sustained Release Tablets

[0051] prescription:

[0052]

[0053] Preparation Process:

[0054] According to the proportion of the prescription, the raw material is mixed with hypromellose, citric acid is dissolved in ethanol as a wetting agent to make a soft material, granulated, dried, sized, mixed with magnesium stearate, pressed Slice and serve.

[0055] 2 to 3 times a day, 1 tablet each time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a carbidopa / levodopa / folic acid compound medicine composition and the use thereof, and belongs to the technical field of pharmacy. The medicine combination comprises the carbidopa with an officinal dose, the levodopa with an officinal dose, the folic acid compounds with an officinal dose, and a carrier which can be accepted in pharmacy. The dose of the carbidopa is 10-60 mg, the dose of the levodopa is 100-300 mg, and the dose of the folic acid compounds is 0.2-1.6 mg. The medicine combination has the advantages that through synergistic effect of multiple target points, curative effect on the Parkinson's disease is improved, life quality of a patient is improved, through a homocysteine (Hcy) target point, cerebral apoplexy of the patient with the Parkinson's disease can be effectively prevented, occurring risk of the cerebral apoplexy can be effectively lowered, and in addition, the patient can conveniently take medicine.

Description

technical field [0001] The invention relates to a pharmaceutical composition of carbidopa / levodopa / folate compound and its application, belonging to the technical field of pharmacy. Background technique [0002] Parkinson's disease (PD) is a chronic progressive disease of extrapyramidal dysfunction in the central nervous system. The main pathological manifestations of PD are the degeneration of dopamine (DA) neurons in the substantia nigra, and the decrease of the content of central neurotransmitter DA, and the degree of depletion of DA is consistent with the severity of PD; at the same time, it can also be accompanied by acetylcholine (Ach), 5- Abnormality and imbalance of various neurotransmitters such as serotonin (5-HT), norepinephrine (NE), γ-aminobutyric acid, and neuropeptides, resulting in a series of clinical symptoms, such as muscle tremors, stiffness, and postural disturbances , movement difficulties, etc. According to reports, there are about 1.5 million PD pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/519A61K31/198A61P25/16
Inventor 王玉姝
Owner SUZHOU FAMO BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com